Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Combined inhibition of MDM2 and Bcr-Abl tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model.

Carter BZ, Mak PY, Mu H, Wang X, Tao W, Mak DH, Dettman EJ, Cardone M, Zernovak O, Seki T, Andreeff M.

Haematologica. 2019 Aug 1. pii: haematol.2019.219261. doi: 10.3324/haematol.2019.219261. [Epub ahead of print]

2.

Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia.

Kannan S, Aitken MJL, Herbrich SM, Golfman LS, Hall MG, Mak DH, Burks JK, Song G, Konopleva M, Mullighan CG, Chandra J, Zweidler-McKay PA.

Mol Cancer Ther. 2019 Sep;18(9):1615-1627. doi: 10.1158/1535-7163.MCT-18-0706. Epub 2019 Jun 21.

3.

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.

Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Koller PB, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M.

Haematologica. 2020 Mar;105(3):697-707. doi: 10.3324/haematol.2018.205534. Epub 2019 May 23.

4.

Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia.

Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes J, Liu Q, Andreeff M, Carter BZ.

Clin Cancer Res. 2018 May 15;24(10):2417-2429. doi: 10.1158/1078-0432.CCR-17-1556. Epub 2018 Feb 20.

5.

Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy.

Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK.

Oncotarget. 2017 Aug 24;8(57):96496-96505. doi: 10.18632/oncotarget.20410. eCollection 2017 Nov 14.

6.

Rapid monoisotopic cisplatin based barcoding for multiplexed mass cytometry.

McCarthy RL, Mak DH, Burks JK, Barton MC.

Sci Rep. 2017 Jun 19;7(1):3779. doi: 10.1038/s41598-017-03610-2.

7.

Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.

Zhou H, Mak PY, Mu H, Mak DH, Zeng Z, Cortes J, Liu Q, Andreeff M, Carter BZ.

Leukemia. 2017 Oct;31(10):2065-2074. doi: 10.1038/leu.2017.87. Epub 2017 Mar 21.

8.

Focal Adhesion Kinase as a Potential Target in AML and MDS.

Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak DH, Mu H, Ruvolo VR, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M.

Mol Cancer Ther. 2017 Jun;16(6):1133-1144. doi: 10.1158/1535-7163.MCT-16-0719. Epub 2017 Mar 7.

9.

Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.

Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Huang X, Cortes J, Kantarjian H, Konopleva M, Andreeff M.

Sci Transl Med. 2016 Sep 7;8(355):355ra117. doi: 10.1126/scitranslmed.aag1180.

10.

MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.

Zeng Z, Wang RY, Qiu YH, Mak DH, Coombes K, Yoo SY, Zhang Q, Jessen K, Liu Y, Rommel C, Fruman DA, Kantarjian HM, Kornblau SM, Andreeff M, Konopleva M.

Oncotarget. 2016 Aug 23;7(34):55083-55097. doi: 10.18632/oncotarget.10397.

11.

Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network.

Carter BZ, Mak PY, Chen Y, Mak DH, Mu H, Jacamo R, Ruvolo V, Arold ST, Ladbury JE, Burks JK, Kornblau S, Andreeff M.

Oncotarget. 2016 Apr 12;7(15):20054-67. doi: 10.18632/oncotarget.7911.

12.

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.

Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, Andreeff M.

Oncotarget. 2015 Oct 13;6(31):30487-99. doi: 10.18632/oncotarget.5890.

13.

Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.

Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, Schober W, McQueen TJ, Cortes J, Tanner SD, Roboz GJ, Kantarjian HM, Kornblau SM, Guzman ML, Andreeff M, Konopleva M.

Cytometry A. 2015 Apr;87(4):346-56. doi: 10.1002/cyto.a.22628. Epub 2015 Jan 16.

14.

Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.

Mak PY, Mak DH, Ruvolo V, Jacamo R, Kornblau SM, Kantarjian H, Andreeff M, Carter BZ.

Br J Haematol. 2014 Nov;167(3):376-84. doi: 10.1111/bjh.13054. Epub 2014 Jul 31. Erratum in: Br J Haematol. 2015 Nov;171(3):440.

15.

Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.

Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger JM, Mu H, Tibes R, Yao H, Coombes KR, Jacamo RO, McQueen T, Kornblau SM, Andreeff M.

J Natl Cancer Inst. 2014 Feb;106(2):djt440. doi: 10.1093/jnci/djt440.

16.

Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML.

Mak PY, Mak DH, Mu H, Shi Y, Ruvolo P, Ruvolo V, Jacamo R, Burks JK, Wei W, Huang X, Kornblau SM, Andreeff M, Carter BZ.

Apoptosis. 2014 Apr;19(4):698-707. doi: 10.1007/s10495-013-0954-z.

17.

XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells.

Carter BZ, Mak DH, Wang Z, Ma W, Mak PY, Andreeff M, Davis RE.

Leuk Res. 2013 Aug;37(8):974-9. doi: 10.1016/j.leukres.2013.04.018. Epub 2013 May 10.

18.

Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.

Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, Mills GB, Andreeff M, Kornblau SM.

Blood. 2012 Jul 5;120(1):173-80. doi: 10.1182/blood-2012-02-409888. Epub 2012 May 29.

19.

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.

Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M.

Leukemia. 2012 Apr;26(4):778-87. doi: 10.1038/leu.2011.287. Epub 2011 Nov 8.

20.

Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.

Mak DH, Wang RY, Schober WD, Konopleva M, Cortes J, Kantarjian H, Andreeff M, Carter BZ.

Leukemia. 2012 Apr;26(4):788-94. doi: 10.1038/leu.2011.285. Epub 2011 Oct 28.

21.

MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML.

Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, Plunkett W, Andreeff M.

Leukemia. 2012 Mar;26(3):443-50. doi: 10.1038/leu.2011.246. Epub 2011 Sep 9.

22.

Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML.

Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA, Ravandi F, Kantarjian HM, Koller E, Andreeff M, Kornblau SM.

Blood. 2011 Jan 20;117(3):780-7. doi: 10.1182/blood-2010-04-280503. Epub 2010 Nov 1.

23.

XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML.

Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian H, Andreeff M.

Apoptosis. 2011 Jan;16(1):67-74. doi: 10.1007/s10495-010-0545-1.

24.

The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?

Carter BZ, Mak DH, Cortes J, Andreeff M.

Semin Hematol. 2010 Oct;47(4):362-70. doi: 10.1053/j.seminhematol.2010.06.006. Review.

25.

Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML.

Carter BZ, Mak DH, Schober WD, Koller E, Pinilla C, Vassilev LT, Reed JC, Andreeff M.

Blood. 2010 Jan 14;115(2):306-14. doi: 10.1182/blood-2009-03-212563. Epub 2009 Nov 6.

26.

Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.

Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ.

Mol Cancer Ther. 2009 Sep;8(9):2509-16. doi: 10.1158/1535-7163.MCT-09-0386. Epub 2009 Sep 1.

27.

Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.

Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M.

J Clin Oncol. 2009 Oct 1;27(28):4741-6. doi: 10.1200/JCO.2009.21.8172. Epub 2009 Aug 3.

28.

Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells.

Carter BZ, Mak DH, Woessner R, Gross S, Schober WD, Estrov Z, Kantarjian H, Andreeff M.

Leukemia. 2009 Oct;23(10):1755-62. doi: 10.1038/leu.2009.101. Epub 2009 May 21.

29.

Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.

Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT, Reed JC, Andreeff M.

Blood. 2008 Apr 1;111(7):3742-50. doi: 10.1182/blood-2007-05-091504. Epub 2008 Jan 10.

30.

Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin.

Mak DH, Schober WD, Chen W, Heller J, Andreeff M, Carter BZ.

Leuk Lymphoma. 2007 Apr;48(4):774-85.

PMID:
17454637
31.

Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance.

Carter BZ, Mak DH, Shi Y, Schober WD, Wang RY, Konopleva M, Koller E, Dean NM, Andreeff M.

Cell Cycle. 2006 Oct;5(19):2223-9. Epub 2006 Oct 1.

PMID:
16969080
32.
33.

A characteristic pharmacological action of 'Yang-invigorating' Chinese tonifying herbs: enhancement of myocardial ATP-generation capacity.

Ko KM, Leon TY, Mak DH, Chiu PY, Du Y, Poon MK.

Phytomedicine. 2006 Nov;13(9-10):636-42. Epub 2006 May 2.

PMID:
16647252
34.

Effects of schisandrin B enantiomers on cellular glutathione and menadione toxicity in AML12 hepatocytes.

Chiu PY, Leung HY, Poon MK, Mak DH, Ko KM.

Pharmacology. 2006;77(2):63-70. Epub 2006 Apr 21.

PMID:
16636610
36.

Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells.

Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL, Andreeff M.

Blood. 2006 Jul 15;108(2):630-7. Epub 2006 Mar 23.

37.

Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.

Carter BZ, Mak DH, Schober WD, Cabreira-Hansen M, Beran M, McQueen T, Chen W, Andreeff M.

Blood. 2006 Feb 15;107(4):1555-63. Epub 2005 Oct 27.

38.

Role of cytochrome P-450 in schisandrin B-induced antioxidant and heat shock responses in mouse liver.

Chiu PY, Mak DH, Poon MK, Ko KM.

Life Sci. 2005 Oct 21;77(23):2887-95. Epub 2005 Jun 14.

PMID:
15958272
39.

Pharmacological basis of 'Yin-nourishing' and 'Yang-invigorating' actions of Cordyceps, a Chinese tonifying herb.

Siu KM, Mak DH, Chiu PY, Poon MK, Du Y, Ko KM.

Life Sci. 2004 Dec 10;76(4):385-95.

PMID:
15530501
40.

A yang-promoting Chinese herbal suppository preparation enhances the antioxidant status of red cells in male human subjects.

Mak DH, Chiu PY, Poon MK, Ng TT, Chung YK, Lam BY, Du Y, Ko KM.

Phytother Res. 2004 Jul;18(7):525-30.

PMID:
15305310
41.

Metformin protects against carbon tetrachloride hepatotoxicity in mice.

Poon MK, Chiu PY, Mak DH, Ko KM.

J Pharmacol Sci. 2003 Dec;93(4):501-4.

42.

Pharmacological basis of 'Yang-invigoration' in Chinese medicine.

Ko KM, Mak DH, Chiu PY, Poon MK.

Trends Pharmacol Sci. 2004 Jan;25(1):3-6. Review.

PMID:
14723971
43.

Hepatoprotective mechanism of schisandrin B: role of mitochondrial glutathione antioxidant status and heat shock proteins.

Chiu PY, Tang MH, Mak DH, Poon MK, Ko KM.

Free Radic Biol Med. 2003 Aug 15;35(4):368-80.

PMID:
12899939
45.

Schisandrin B protects against tacrine- and bis(7)-tacrine-induced hepatotoxicity and enhances cognitive function in mice.

Pan SY, Han YF, Carlier PR, Pang YP, Mak DH, Lam BY, Ko KM.

Planta Med. 2002 Mar;68(3):217-20.

PMID:
11914957
48.

Myocardial protective effect of an anthraquinone-containing extract of Polygonum multiflorum ex vivo.

Yim TK, Wu WK, Mak DH, Ko KM.

Planta Med. 1998 Oct;64(7):607-11.

PMID:
9810265
50.

Effects of Schisandrin B and alpha-tocopherol on lipid peroxidation, in vitro and in vivo.

Mak DH, Ip SP, Li PC, Poon MK, Ko KM.

Mol Cell Biochem. 1996 Dec 20;165(2):161-5.

PMID:
8979266

Supplemental Content

Support Center